AbCellera Biologics Inc.

Antibody-discovery platform company transitioning into a clinical-stage biotech with its own internal pipeline, leveraging proprietary GPCR, ion-channel, and multipass-membrane-protein discovery technologies. Lead programs ABCL635 (anti-NK3R for menopausal vasomotor symptoms) and ABCL575 (anti-OX40L for atopic dermatitis) are in the clinic, with first readouts expected in 2026.